Expertise in
9
conditions

Hong M. Guo

Chongqing, CN 
Expertise in
9
conditions
Chongqing, CN 
OverviewLocationsClinical Research

Overview

Hong Guo practices in Chongqing, China. Ms. Guo is highly rated in 9 conditions, according to our data. Her top areas of expertise are Viral Gastroenteritis, Helicobacter Pylori Infection, Acute Myeloid Leukemia (AML), Endoscopy, and Mastectomy.

Her clinical research consists of co-authoring 200 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Chongqing, 401147, China
Other Locations
118 Xingguang Avenue, Yubei, 401147, China
30 Gaotanyan Main Street, Tanjiagang, 400038, China
Daping, China
Yangzhou, China
Nanjing, China
Baotou, China
Jinan, China
Xinqiao, China
Dongguan, China
Shantou, 515041, China
Hohhot, China
No. 118, Xingguang Avenue, Liangjiang New Area, Xingguang, 401147, China
Shenyang, China
State Key Laboratory Of Crop Biology, Key Laboratory Of Crop Biology Of Shandong Province, P.R. China, Tai'an, 271000, China
Yantai, China
Guangzhou, 510632, China
Zhenjiang, China
China
State Key Laboratory Of Quality Research In Chinese Medicine, Macao, China
Shanghai, China
Beijing, China
Zibo, 255049, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-World Clinical Practice in China
A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-World Clinical Practice in China
Enrollment Status: Completed
Publish Date: July 22, 2024
View 4 Less Clinical Trials

200 Total Publications

A Reference Atlas of the Human Dorsal Root Ganglion.
A Reference Atlas of the Human Dorsal Root Ganglion.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Guo's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 41 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile